Reduction mammaplasty improves symptoms of macromastia

The condition macromastia has not been defined and characterized precisely by the medical community. Whether the patient with hypertrophic breasts is a candidate for or can be helped by reduction mammaplasty is unclear to both the medical and the lay community. A prospective study of 39 women undergoing reduction mammaplasty surgery was initiated to answer these questions. Patients rated the severity of their somatic pain symptoms and discomfort before reduction mammaplasty and again after complete recovery. The severity of their symptoms and complaints was numerically graded and analyzed. These data were compared with similar data obtained from 40 "small-breasted" women of similar age. Headache, neck pain, back pain, shoulder pain, and bra strap groove pain were present in 60 to 92 percent of patients, and 97 percent of patients had at least three of these pain symptoms preoperatively. All the patients had reduction of their pain symptomatology postoperative, and 25 percent of the study patients had total elimination of pain symptoms by reduction mammaplasty. The postoperative incidence and severity of pain symptoms and discomfort complaints were statistically equivalent to or less than the levels in the control group.     

Cytomorphometric markers for uterine cancer in intermediate cells

Precise microphotometric assessment of intermediate cells from patients with normal cervical cytology and from patients with dysplasia or carcinoma in situ shows the existence of small but consistent differences. Marker features for the presence of premalignant and malignant disease can be extracted from the cell images of "normal"-appearing intermediate cells. The marker features and their diagnostic classification potential are described.     

随机算法异步并行化的效率分析

随机算法的执行时间具有不确定性,这种不确定性为随机算法的异步并行提供了良好的基础,已有许多计算实验表明了随机算法的异步并行可以达到线性甚至超线性的加速.对于求解SAT问题的随机算法RDP,研究了异步并行效率与运行时间分布和处理器数目之间的关系.应用一种单峰分布──分段线性分布模型来模拟随机算法的运行时间分布.理论分析和计算结果均表明:当处理器数目k较小和单峰位于分布的前部时,随机算法的异步并行具有近线性加速.     

Summary of the Closing Session

Plausible costs of photovoltaic power plants of concentration are presented. Costs are based as much as possible on the recent experience of solar thermal plants. Efficiencies, on the existing world experience of PV power plants. The result is that the costs of concentrating photovoltaic plants should be of 0.08 ECUs/ kWh, about 1/3 of that of flat module plants, and of the same order of magnitude, even lower, than those attributed to solar thermal plants of present technology.

For the future, high concentration systems based on Si or tandem cells seem to be the most promising, also in the range of costs of the advanced solar thermal plants.     

Synthesis,structural characterization,and photocatalytic properties of iron-doped TiO<Subscript>2</Subscript> aerogels

Fe(III)-doped TiO₂ aerogels are prepared by acid catalyzed sol–gel method followed by supercritical drying, and then heat treatment. Raman spectra together with X-ray diffraction (XRD) and selected area electron diffraction (SAED) patterns of the iron-doped TiO₂ aerogel samples revealed the existence of both anatase and brookite crystalline phases. It was found that the brookite phase formation is favored by the increase of the iron content in the dried samples. XRD measurements show that the lattice constant c of anatase phase decreases with the dopant addition, while the value of a remains essentially unchanged. The microstructure of the investigated samples is relatively compact with small mesopores as revealed from transmission electron microscopy (TEM). The most enhanced photocatalytic activity was exhibited by the TiO₂ aerogel sample with 1.8 at.% Fe(III) whose apparent rate constant of the salicylic acid photodegradation was found to be of almost six times higher than that of Degussa P25.     

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

PURPOSE: Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I). Based on the strategy of fractionating the total dose, this study was designed to define the maximum-tolerated dose (MTD) and efficacy of the first two, of a maximum of four, doses of (131)I-Lym-1 given 4 weeks apart. Additionally, toxicity and radiation dosimetry were assessed. MATERIALS AND METHODS: Twenty patients with advanced NHL entered the study a total of 21 times. Thirteen (62%) of the 21 entries had diffuse large-cell histologies. All patients had disease resistant to standard therapy and had received a mean of four chemotherapy regimens. (131)I-Lym-1 was given after Lym-1 and (131)I was escalated in cohorts of patients from 40 to 100 mCi (1.5 to 3.7 GBq)/m2 body surface area. RESULTS: Mean radiation dose to the bone marrow from body and blood (131)I was 0.34 (range, 0. 1 6 to 0.63) rad/mCi (0.09 mGy/MBq; range, 0.04 to 0.17 mGy/ MBq). Dose-limiting toxicity was grade 3 to 4 thrombocytopenia with an MTD of 100 mCi/m2 (3.7 GBq/m2) for each of the first two doses of (131)I-Lym-1 given 4 weeks apart. Nonhematologic toxicities did not exceed grade 2 except for one instance of grade 3 hypotension. Ten (71 %) of 14 entries who received at least two doses of (131)I-Lym-1 therapy and 11 (52%) of 21 total entries responded. Seven of the responses were complete, with a mean duration of 14 months. All three entries in the 100 mCi/m2 (3.7 MBq/m2) cohort had complete remissions (CRs). All responders had at least a partial remission (PR) after the first therapy dose of (131)I-Lym-1. CONCLUSION: (131)I-Lym-1 induced durable remissions in patients with NHL resistant to chemotherapy and was associated with acceptable toxicity. The nonmyeloablative MTD for each of the first two doses of (131)I-Lym-1 was 100 mCi/m2 (total, 200 mCi/m2) (3.7 GBq/m2; total, 7.4 GBq/m2).     

Defective repair of oxidative damage in mitochondrial DNA in Down''s syndrome

BACKGROUND: Synthetic homopyrimidine peptide nucleic acids (PNAs) can bind complementary targets in double-stranded DNA, generating strand-displacement complexes, and so offering an opportunity to modulate specific gene expression. Several issues remain to be addressed before these attributes can be exploited in vivo, however. RESULTS: The kinetics of the interaction between a homopyrimidine PNA and a complementary homopurine target on double-stranded DNA were analyzed in the presence or absence of a preformed strand-displacement complex proximal to the target. The complex was established under low salt conditions by the binding of a different homopyrimidine PNA to a target situated adjacent to the first PNA target. These two targets were placed next to each other on opposite strands at distances of 0, 2, 4 and 8 base pairs apart. The presence of a preformed strand-displacement complex near the target accelerates the binding of PNA to double-stranded DNA in a salt-dependent manner. The influence of salt on the binding rates was also examined. The binding rate is increased by a factor of 1 x exp(70[NaCl]), that is, 16-fold at 40 mM NaCl and more than 10(4)-fold if extrapolated to 140 mM NaCl. This effect is significantly reduced if the two targets are 2 base pairs apart and completely absent if the distance is 4 base pairs or more. CONCLUSIONS: The perturbation of the DNA helix imposed by a PNA strand-displacement complex only propagates a few base pairs. It is therefore possible to target sites in the immediate vicinity of strand invasion complexes specifically. The results presented have implications for the mechanism of strand displacement and for the application of PNA in a genomic context.